Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine.

Autor:	Machet A; Department of Hematology and Cell Therapy, University Hospital of Poitiers, Poitiers, France., Poudou C; Department of Medically Assisted Procreation, University Hospital of Poitiers, Poitiers, France., Tomowiak C; Department of Hematology and Cell Therapy, University Hospital of Poitiers, Poitiers, France., Gastinne T; Department of Hematology, University Hospital of Nantes, Nantes, France., Gardembas M; Department of Hematology, University Hospital of Angers, Angers, France., Systchenko T; Department of Hematology and Cell Therapy, University Hospital of Poitiers, Poitiers, France., Moya N; Department of Hematology and Cell Therapy, University Hospital of Poitiers, Poitiers, France., Debiais C; Department of Anatomopathology, University Hospital of Poitiers, Poitiers, France., Levy A; Department of Hematology and Cell Therapy, University Hospital of Poitiers, Poitiers, France., Gruchet C; Department of Hematology and Cell Therapy, University Hospital of Poitiers, Poitiers, France., Sabirou F; Department of Hematology and Cell Therapy, University Hospital of Poitiers, Poitiers, France., Noel S; Department of Hematology and Cell Therapy, University Hospital of Poitiers, Poitiers, France., Bouyer S; Department of Cytology, University Hospital of Poitiers, Poitiers, France., Leleu X; Department of Hematology and Cell Therapy, University Hospital of Poitiers, Poitiers, France., Delwail V; Department of Hematology and Cell Therapy, University Hospital of Poitiers, Poitiers, France., Guidez S; Department of Hematology and Cell Therapy, University Hospital of Poitiers, Poitiers, France.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2023 Aug 08; Vol. 7 (15), pp. 3978-3983.
DOI:	10.1182/bloodadvances.2021005557
Abstrakt:	Preservation of fertility has become a growing concern in young females with Hodgkin lymphoma (HL). However, the rate of pregnancy after the current most frequently prescribed ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and darcarbazine) chemotherapy for HL has rarely been studied. In this study, we aim to determine the impact of ABVD on the fertility of women treated for HL. We conducted a noninterventional, multicenter study of female patients of childbearing age who were treated for HL. Two healthy apparied women nonexposed to chemotherapy (our controls) were assigned for each patient. Fertility was assessed by the number of pregnancies and births after HL treatment. Sixty-seven patients were included. The median age at diagnosis was 24.4 years (range, 16-43). HL was a localized disease for 68.7%. Of all the patients, 53.7% started at least 1 pregnancy after treatment vs 54.5% of the controls (P = .92). Of all the patients who desired children, 81% had at least 1 pregnancy. Patients treated with ABVD did not have a longer median time to pregnancy (4.8 years in the group of patients and 6.8 years for controls). Across patients, there were 58 pregnancies and 48 births (ratio, 1:2) and 136 pregnancies and 104 births (ratio, 1:3) for the control cohort. No increase in obstetric or neonatal complications has been reported in HL in our study. The number of pregnancies, births, and the time to start a pregnancy in young women treated with ABVD for HL is not different from that of controls. Therefore, females with HL treated with ABVD should be reassured regarding fertility. (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu